Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by Luxor101on Nov 05, 2021 1:15pm
227 Views
Post# 34092925

CONSOLIDATION/DILUTION

CONSOLIDATION/DILUTIONConsolidation followed by more dilution definitely hurts the shareholders. They supress any deals and tout how great things will be just to consolidate at a lower price. This management team are the same that got scammed by Mackie. These people are inept when it comes to the equity markets and we have said that from the start. Suggestions continue to not be heard and they think they know better than anyone and they do not. Look at the graphs they generated and now removed, revenue in Q4 2020. This is misleading and several statements by Elliott have been out right lies and now we should trust them to make the right decisions on a rollback. Look at the facts not suppositions made by this management crew. I believe they are already lined up to go on the NASDAQ and will not wait to see the shares appreciate as Elliott only enjoys a cheap valuation and will undoubtably issue himself more options at a discount so he does not get affected. 
<< Previous
Bullboard Posts
Next >>